U.S. markets close in 1 hour 14 minutes

Adamas Pharmaceuticals, Inc. (ADMS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.8200+0.0400 (+0.84%)
As of 2:46PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close4.7800
Open4.8300
Bid4.8100 x 800
Ask4.8300 x 1000
Day's Range4.7500 - 4.8500
52 Week Range2.9600 - 9.1500
Volume48,852
Avg. Volume233,132
Market Cap219.772M
Beta (5Y Monthly)2.68
PE Ratio (TTM)N/A
EPS (TTM)-1.6010
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.79
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Adamas Pharmaceuticals, Inc.
    JAZZ: Lowering target price to $146.00JAZZ PHARMACEUTICALS PLC has an Investment Rating of BUY; a target price of $146.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • Business Wire

    Adamas Announces GOCOVRI Presentations at the Upcoming International Parkinson and Movement Disorder Society’s (MDS) Congress

    EMERYVILLE, Calif., September 16, 2021--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced five posters will be presented at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress, taking place September 17 – 22, 2021. The poster presentations will focus on GOCOVRI® (amantadine) extended-release capsules, the first and only

  • Business Wire

    Adamas Announces New Employment Inducement Grants

    EMERYVILLE, Calif., September 10, 2021--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted seven new employees restricted stock units to acquire 94,750 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) o

  • Business Wire

    Adamas to Present at Upcoming September Investor Conferences

    EMERYVILLE, Calif., August 30, 2021--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that management will present at the following virtual investor conferences during the month of September 2021: